Completed
PHASE2
INTERVENTIONAL
NCT02178488
Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) Carriers
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to treat persistent MRSA carriers with vitamin D supplementation during a 12 month to see if the number of MRSA positive patients can be reduced.
Interventions
Name:
Cholecalciferol
Type:
DRUG
Description:
Cholecalciferol 4000 IU/day for 12 months
Name:
Placebo
Type:
OTHER
Description:
Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
Primary Outcomes
Measure:
MRSA
TimeFrame:
Baseline, 3, 6, 9 and 12 months
Description:
The primary endpoint is the decline of MRSA-positive patients during a 12-month period in the treatment groups (vitamin D/Placebo) based on 5 measurements with 3 months interval.
Trial Information
NCT ID
NCT02178488
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Peter Bergman
Last Updated
December 15, 2025